🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are escalating globally, with estimates suggesting over 82 million new cases per year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the face of rising global incidence, the spread of superbugs and the highly restricted available drugs at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the management of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Data and Global Access

Based on data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which combines a dual-drug approach. The research enrolled hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the authority to license and sell the drug in many low-income and middle-income countries.

Clinicians directly involved have voiced hope. The availability of a one-pill regimen such as this is described as a "game-changer" for public health efforts. This is viewed as crucial to reduce the burden of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.